

CHARLES D. BAKER Governor

KARYN E. POLITO Lieutenant Governor

MARYLOU SUDDERS Secretary The Commonwealth of Massachusetts Executive Office of Health and Human Services One Ashburton Place, Room 1109 Boston, Massachusetts 02108

> Tel: (617) 573-1600 Fax: (617) 573-1891 www.mass.gov/eohhs

Administrative Bulletin 18-23

101 CMR 320.00 Clinical Laboratory Services

Effective January 1, 2018

Procedure Code Update

Under the authority of regulation 101 CMR 320.01(3), the Executive Office of Health and Human Services is adding new procedure codes and deleting outdated codes. Per the regulation, the rates for code additions are priced at 74.67% of the prevailing Medicare rate, if available. If Medicare rates are unavailable, services are priced at individual consideration. The rate for new code replacements were set at the rate previously set for the replaced codes. The changes, effective January 1, 2018, are as follows.

| Code | Change | Rate | Code Description (if applicable) |
|-------|----------|----------|---|
| 81105 | Addition | \$112.67 | Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P) |
| 81106 | Addition | \$112.67 | Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M) |
| 81107 | Addition | \$112.67 | Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin alpha 2b platelet glycoprotein IIb of Iib/IIIa complex], antigen CD41 [GPIIb]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S) |
| 81108 | Addition | \$112.67 | Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q) |
| 81109 | Addition | \$112.67 | Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin alpha 2 subunit of VLA-2 receptor] [(GPla]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant,(e.g., HPA- 5a/b (K505E)) |
| 81110 | Addition | \$112.67 | Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (R489Q) |
| 81111 | Addition | \$112.67 | Human Platelet Antigen 9 genotyping (HPA -9w), ITGA2B (integrin, alpha 2b |

| | | | (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (e.g., |
|--------|------------|------------------------|--|
| | | | neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M) |
| | | | Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) |
| 81112 | Addition | \$112.67 | (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion |
| | | | purpura), gene analysis, common variant, HPA-15a/b (S682Y) |
| 81120 | Addition | \$144.30 | IDH1 (isocitrate dehydrogenase 1 [NDDP+], soluble) (e.g., glioma), common variants (e.g., R132H, R132C) |
| | | | IDH2 (isocitrate dehydrogenase 2 [NDDP+], mitochondrial) (e.g., glioma), |
| 81121 | Addition | \$220.87 | common variants (e.g., R140W, R172M) |
| | | | ASXL (additional sexcombs like 1, transcriptional regulator) (e.g., |
| 81175 | Addition | \$527.93 | myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene |
| | | | analysis; full gene sequence |
| | | \$222 00 | ASXL (additional sexcombs like 1, transcriptional regulator) (e.g., |
| 81176 | Addition | \$222.99 | myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene |
| | | | analysis; targeted sequence analysis (e.g., exon 12) CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (e.g., drug |
| 81230 | Addition | \$130.53 | metabolism), gene analysis, common variants (e.g., *2, *22), |
| | | * 100 70 | CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (e.g., drug |
| 81231 | Addition | \$130.53 | metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *7) |
| | | | DPYD (dihydropyrimidine dehydrogenase) (e.g., 5-fluorouracil/5-FU and |
| 81232 | Addition | \$130.53 | capecitabine drug metabolism), gene analysis, common variant(s) (e.g., *2A, *4, |
| | | | *5, *6) |
| 81238 | Addition | \$448.02 | F9 (coagulation factor IX) (e.g., hemophilia B), full gene sequence |
| 81247 | Addition | \$130.53 | G6PD (glucose-6-phosphate dehydrogenase) (e.g., hemolytic anemia, jaundice), |
| 012-17 | Rudition | φ150.55 | gene analysis; common variant(s) (e.g., A, A-) |
| 81248 | Addition | \$280.20 | G6PD (glucose-6-phosphate dehydrogenase) (e.g., hemolytic anemia, jaundice), |
| | | + | gene analysis; known familial variant(s) G6PD (glucose-6-phosphate dehydrogenase) (e.g., hemolytic anemia, jaundice), |
| 81249 | Addition | \$448.02 | gene analysis; full gene sequence |
| | | | HBA 1/HBA 2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb |
| 81258 | Addition | \$280.20 | Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial |
| | | | variant |
| 81259 | Addition | \$448.02 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb |
| 01207 | Tuullon | ¢110.02 | Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene analysis |
| 81269 | Addition | \$151.13 | HBA 1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; |
| 01209 | Addition | \$131.13 | duplication/deletion variants |
| | | ** < 22 | IFNL3 (interferon, lambda 3) (e.g., drug response), gene analysis, rs 12979860 |
| 81283 | Addition | \$56.33 | variant |
| 81328 | Addition | \$130.53 | SLCO1B1 (solute carrier organic anion transporter family, member 1B1 (e.g., |
| 01520 | Addition | φ130.33 | adversedrug reaction), gene analysis, common variants(s) (e.g.,*5) |
| 01004 | | \$246.04 | RUNX1 (runt related transcription factor 1) (e.g., acute myeloid leukemia, |
| 81334 | Addition | \$246.04 | familial platelet disorder with associated myeloid malignancy), gene analysis, |
| | | | targeted sequence analysis (e.g., exons 3-8) TPMT (thipurine S-methyltransferase) (e.g., drug metabolism), gene analysis, |
| 81335 | Addition | \$130.53 | common variants (e.g., *2, *3) |
| 01016 | | ¢100.50 | TYMS (thymidylate synthetase) (e.g., 5-fluorouracil/5-FU drug metabolism), |
| 81346 | Addition | \$130.53 | gene analysis, common variant(s) (e.g., tandem repeat variant) |
| 81361 | Addition | \$130.53 | HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, |
| 01501 | / www.ioii | φ150.55 | hemoglobinopathy); common variant(s) (e.g., HbS, HbC, HbE) |
| 81362 | Addition | \$280.20 | HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, |
| | | | hemoglobinopathy); known familial variant(s) HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, |
| 81363 | Addition | \$151.13 | hemoglobinopathy); duplication/deletion variant(s) |
| 010-1 | A 1 11.1 | #0.10.0 5 | HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, |
| 81364 | Addition | \$242.36 | hemoglobinopathy); full gene sequence |
| 81448 | Addition | \$539.19 | |
| | | \$2314.04 | Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 |

| | | | genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin- embedded tis sue, algorithm reported as a recurrence risk score |
|-------|--------------|-----------|---|
| 81521 | Addition | \$2891.97 | Oncology (breast), mRNA microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk or distant metasis |
| 81541 | Addition | \$2891.97 | Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin- embedded tis sue, algorithm reported as a disease specific mortality risk score |
| 81551 | Addition | \$2314.04 | Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy |
| 83499 | Discontinued | | |
| 84061 | Discontinued | | |
| 86008 | Addition | \$16.53 | Allergen specific IgE; quantitative or semi quantitative, recombinant or purified component, each |
| 86185 | Discontinued | | |
| 86243 | Discontinued | | |
| 86378 | Discontinued | | |
| 86729 | Discontinued | | |
| 86794 | Addition | \$15.53 | Zika virus, IgM |
| 86822 | Discontinued | | |
| 87277 | Discontinued | | |
| 87470 | Discontinued | | |
| 87477 | Discontinued | | |
| 87515 | Discontinued | | |
| 87634 | Addition | \$64.71 | Respiratory syncytial virus, amplified probe technique |
| 87662 | Addition | \$47.30 | Zika Virus, amplified probe technique |
| 88154 | Discontinued | | |